Ngangom Robert

Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

The relationship between prognostic and predictive factors in the management of breast cancer

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

p53 and chemosensitivity

<i>p53</i> Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon Carcinoma

Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata

Legumes and soybeans: overview of their nutritional profiles and health effects

Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry

Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

Angiogenesis and Blood Vessel Invasion as Prognostic Indicators for Node-Negative Breast Cancer

The Ki-67 protein: From the known and the unknown

Clonal evolution in cancer

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Repeated observation of breast tumor subtypes in independent gene expression data sets

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Accumulation of p53 Protein as a Possible Predictor of Response to Adjuvant Combination Chemotherapy With Cyclophosphamide, Methotrexate, Fluorouracil, and Prednisone for Breast Cancer